Trishula Therapeutics
TTX-030 | anti-CD39 antibody
- Headquarters
- South San Francisco, California
- Business Model
- B2B
- Website
- trishulatx.com
About
Clinical-stage biotech developing TTX-030, a first-in-class anti-CD39 antibody for cancer immunotherapy.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSimilar Companies
inVentiv HealthAcquired
Biopharmaceutical services company
United States5001–10000Biotech, Healthcare
Private Equity·$3.0B·May 2017
WC
Warner ChilcottAcquired
Specialty pharmaceutical company
Rockaway, United States1001–5000Biotech, Healthcare
Private Equity·$3.0B·Jan 2004
AsymchemIPO
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Tianjin, China5001–10000Healthcare, Biotech
Private Equity·$2.3B·Feb 2020
Hugel
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Chuncheon, South Korea201–500Aesthetics, Biotech
Private Equity·$2.3B·Aug 2021
N
Novotech
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Sydney, Australia1001–5000Biotech, Healthcare
Growth Equity·$1.9B·Mar 2025
Celerion (H.I.G. Capital)
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Lincoln, United States501–1000Biotech, Healthcare
Private Equity·$1.8B·Apr 2026